Used in targeted cancer therapies, particularly for glioblastoma and other solid tumors overexpressing EGFR. This antibody selectively binds to the extracellular domain of EGFR, inhibiting receptor activation and downstream signaling pathways involved in tumor cell proliferation, survival, and migration. It serves as a reference reagent in preclinical studies to evaluate the efficacy and binding characteristics of experimental anti-EGFR antibodies. Also utilized in immunohistochemistry and flow cytometry to detect EGFR expression in tumor tissues, aiding in patient stratification for EGFR-targeted treatments. Its well-characterized specificity makes it valuable for standardizing assays in diagnostic development and therapeutic antibody research.